Adagene Inc - ADR
ADAG
Get informed when a big investor buys or sells
+ FollowMarket Cap$124.62M
Close$
$1.68
48.1% downside
Current Fair Value
48.1% downsideOvervalued by 48.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.62 Million |
|---|---|
| Enterprise Value | $4.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 0.56 |
| Outstanding Shares | 45,295,212 |
Return
| Return on Equity | -55.64% |
|---|---|
| Return on Assets | -44.16% |
| Return on Invested Capital | -55.03% |
Valuation & Multiples
| P/E Ratio | -7.01 |
|---|---|
| PEG | -32.65 |
| Price to Sales | - |
| Price to Book Ratio | 1.62 |
| Enterprise Value to Revenue | 0.53 |
| Enterprise Value to EBIT | -0.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.66 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$17.50 M
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.52%▲ 33.78% |
|---|---|
| Total Invested | $81.00M▲ 735.05% |
| Investors Holding | 36▲ 11.00% |
ESG Score
No data
About Adagene Inc
2,020 employeesAdagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial int...